A recent Danish observational study of women with early breast cancer [14] reported no increased risk of recurrence or mortality associated with vaginal oestrogen use; however an increased risk of breast cancer recurrence was seen in a subgroup analysis of women on aromatase inhibitors. The gene discussed is CYP19A1; the disease is breast cancer.